1. Home
  2. WEX vs DNTH Comparison

WEX vs DNTH Comparison

Compare WEX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WEX Inc. common stock

WEX

WEX Inc. common stock

HOLD

Current Price

$197.77

Market Cap

6.1B

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$77.07

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEX
DNTH
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
5.9B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
WEX
DNTH
Price
$197.77
$77.07
Analyst Decision
Buy
Strong Buy
Analyst Count
15
17
Target Price
★ $195.36
$140.80
AVG Volume (30 Days)
461.0K
★ 865.0K
Earning Date
10-28-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.93
N/A
EPS
★ 5.33
N/A
Revenue
★ $2,660,800,000.00
$2,036,000.00
Revenue This Year
$8.92
N/A
Revenue Next Year
$1.57
N/A
P/E Ratio
$37.18
★ N/A
Revenue Growth
★ 1.24
N/A
52 Week Low
$125.29
$32.28
52 Week High
$203.99
$117.88

Technical Indicators

Market Signals
Indicator
WEX
DNTH
Relative Strength Index (RSI) 69.70 33.18
Support Level $183.52 $75.50
Resistance Level $203.97 $91.36
Average True Range (ATR) 4.68 4.05
MACD 3.16 0.51
Stochastic Oscillator 96.34 40.47

Price Performance

Historical Comparison
WEX
DNTH

About WEX WEX Inc. common stock

WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: